Enterprise Therapeutics Secures EMA Orphan Drug Designation for Cystic Fibrosis Candidate
Key Points
- The EMA granted orphan designation to ETD001, Enterprise Therapeutics' inhaled ENaC blocker for cystic fibrosis, especially for patients unable to use CFTR modulators.
- The designation follows positive Phase 2 ET-ENAC-03 results and offers incentives including possible 10 years of EU market exclusivity after authorization.
- Cystic fibrosis affects more than 100,000 people worldwide, causing thick mucus, recurrent infections and progressive lung decline.
Enterprise Therapeutics has received orphan medicinal product designation from the European Medicines Agency (EMA) for ETD001, its investigational inhaled therapy being developed for people with cystic fibrosis (CF). The designation, granted following a positive opinion from the EMA’s Committee for Orphan Medicinal Products (COMP), recognizes the potential of ETD001 to address an unmet medical need in a rare and serious disease. The therapy is being developed particularly for patients who are unable to take advantage of existing CFTR modulator treatments.
ETD001 is an inhaled epithelial sodium channel (ENaC) blocker designed to improve the lungs’ ability to clear mucus. By targeting sodium transport in the airways, the investigational treatment aims to improve mucus hydration and clearance, helping reduce airway obstruction and support lung function.
The regulatory decision follows positive results from the Phase 2 ET-ENAC-03 clinical trial, which provided clinical evidence indicative of improvements in lung function. These findings helped support the EMA’s assessment of the therapy’s potential clinical benefit.
Orphan medicinal product designation provides several development and commercial incentives, including regulatory support and the possibility of 10 years of market exclusivity in the European Union following marketing authorization, subject to applicable conditions.
“Orphan drug designation represents an important regulatory milestone for the ETD001 program and for Enterprise Therapeutics,” says Dr. John Ford, CEO of Enterprise Therapeutics. He notes that the decision highlights the continuing need for additional treatment options, particularly for people with CF who cannot benefit from CFTR modulators. The company plans to advance ETD001 development in cystic fibrosis and other respiratory conditions associated with mucus congestion.
Annabella Amatulli, Head of Regulatory Affairs at Enterprise Therapeutics, says the designation supports the company’s global development strategy for ETD001 and reflects the scientific rationale and clinical findings generated to date.
Cystic fibrosis is a progressive genetic disease estimated to affect more than 100,000 people worldwide. The condition disrupts the movement of salt and water across cell membranes, resulting in the production of thick, sticky mucus that can accumulate in the lungs. Impaired mucociliary clearance contributes to recurrent infections, chronic inflammation and progressive deterioration in lung function, ultimately reducing life expectancy.
Although CFTR modulators have improved outcomes for many people with cystic fibrosis, additional therapeutic approaches remain necessary for patients who are ineligible for these treatments or do not achieve sufficient benefit from them.
Additional information is available at www.enterprisetherapeutics.com.
Total Page Views: 9

















